Episode
Ep138: Amyloid busters- the benefit and the burden
- Podcast
- Pomegranate Health
- Published
- Oct 8, 2025
- Duration seconds
- 3365
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/pomegranate-health-4653/episodes/ep138-amyloid-busters-the-benefit-and-the-burden/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/pomegranate-health-4653/ep138-amyloid-busters-the-benefit-and-the-burden.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Australia has just approved a second amyloid-targeting therapy for patients with incipient Alzheimer’s dementia. Lecanemab (Leqembi) now joins donanemab (Kisunla) on the Australian Registry of Therapeutic Goods but the impact of both has been modest in Phase III trials to date. After 18 months of therapy they delay progression of disease, as quantified on neurocognitive tests, by around 5 months on average. For some, the prolonged independence and dignity will justify the $60,000...